7
Disclosures
Jan 30, 2026 — Mar 25, 2026
Date Range
PRIME
Market Segment
Pharmaceutical
Sector
Disclosures
| Date | Type | Headline | |
|---|---|---|---|
| Mar 25 | Dividend | Sumitomo Pharma: Reports Non-operating Revenue for Fiscal Year Ending March 2026 | |
| Mar 6 | Other | Sumitomo Pharma Secures Conditional Approval for iPSC-Derived Cell Therapy Amshippri® | |
| Mar 2 | Forecast | FY2026/3 Full-Year Earnings Forecast Upward Revision | |
| Feb 13 | Other | Sumitomo Pharma's iPS Cell-Based Therapy Under Review by Health Ministry Panel | |
| Jan 30 | Earnings | Sumitomo Pharma Co., Ltd. Earnings Presentation: Revenue of 2.93 billion | |
| Jan 30 | Earnings | Sumitomo Pharma Co., Ltd. Reports FY2026 Earnings Presentation: Revenue of 2.93 billion | |
| Jan 30 | Earnings | Sumitomo Pharma Co., Ltd. Reports Q3 Revenue of 293 billion, Up 25% |
Disclosure Types
Earnings: 3 Other: 2 Dividend: 1 Forecast: 1